Literature DB >> 3722385

Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis.

M R Wallace, F E Dwulet, P M Conneally, M D Benson.   

Abstract

Familial amyloidotic polyneuropathy (FAP) is an autosomal dominant late-onset disorder characterized by the extracellular deposition of amyloid fibrils. In all cases studied these fibrils have been found to be composed of plasma prealbumin (transthyretin) containing a single amino acid substitution. Biochemical studies were conducted on amyloid from one patient and plasma prealbumin from his affected brother, both part of a large kindred from the Appalachian region of the United States. Sequence analysis of the amyloid subunit protein showed it to be prealbumin with about two-thirds of the molecules containing a substitution of alanine for threonine at position 60. Studies of the plasma prealbumin showed that the same substitution was present in 40-45% of the protein. Based on this substitution and the prealbumin cDNA sequence, a Pvu II restriction fragment length DNA polymorphism (RFLP) was predicted and demonstrated in DNA of both patients as well as other family members. This RFLP confirms the predicted DNA mutation responsible for the protein variant, and represents an accurate method for detection of this gene.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3722385      PMCID: PMC329523          DOI: 10.1172/JCI112573

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves.

Authors:  C ANDRADE
Journal:  Brain       Date:  1952-09       Impact factor: 13.501

2.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

3.  Hereditary amyloidosis with polyneuropathy.

Authors:  R Andersson
Journal:  Acta Med Scand       Date:  1970 Jul-Aug

4.  A variant prealbumin-related low molecular weight amyloid fibril protein in familial amyloid polyneuropathy of Japanese origin.

Authors:  F Kametani; H Tonoike; A Hoshi; T Shinoda; S Kito
Journal:  Biochem Biophys Res Commun       Date:  1984-12-14       Impact factor: 3.575

5.  Polymorphism of human plasma thyroxine binding prealbumin.

Authors:  F E Dwulet; M D Benson
Journal:  Biochem Biophys Res Commun       Date:  1983-07-29       Impact factor: 3.575

6.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A.

Authors:  C C Blake; M J Geisow; S J Oatley; B Rérat; C Rérat
Journal:  J Mol Biol       Date:  1978-05-25       Impact factor: 5.469

7.  Revised analysis of amino acid replacement in a prealbumin variant (SKO-III) associated with familial amyloidotic polyneuropathy of Jewish origin.

Authors:  M Nakazato; K Kangawa; N Minamino; S Tawara; H Matsuo; S Araki
Journal:  Biochem Biophys Res Commun       Date:  1984-09-28       Impact factor: 3.575

8.  Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin.

Authors:  F E Dwulet; M D Benson
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

9.  Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type).

Authors:  S Tawara; M Nakazato; K Kangawa; H Matsuo; S Araki
Journal:  Biochem Biophys Res Commun       Date:  1983-11-15       Impact factor: 3.575

10.  Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin.

Authors:  M Pras; F Prelli; E C Franklin; B Frangione
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

View more
  34 in total

Review 1.  Amyloidosis.

Authors:  M F Khan; R H Falk
Journal:  Postgrad Med J       Date:  2001-11       Impact factor: 2.401

2.  "Sporadic" prealbumin-related amyloid polyneuropathy: report of two cases.

Authors:  M Yamada; H Tsukagoshi; J Satoh; S Ishiai; M Nakazato; H Furuya; H Sasaki; Y Sakaki; T Yokota
Journal:  J Neurol       Date:  1987-12       Impact factor: 4.849

3.  Combined cardiac and liver transplantation for the treatment of familial amyloidosis.

Authors:  Brian G Schwartz; Johannes J Kuiper; Göran B Klintmalm; Marvin J Stone; Jeffrey M Schussler
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-04

4.  The CpG dinucleotide and human genetic disease.

Authors:  D N Cooper; H Youssoufian
Journal:  Hum Genet       Date:  1988-02       Impact factor: 4.132

5.  A DNA test for Indiana/Swiss hereditary amyloidosis (FAP II).

Authors:  M R Wallace; P M Conneally; M D Benson
Journal:  Am J Hum Genet       Date:  1988-08       Impact factor: 11.025

6.  Characterization of a transthyretin (prealbumin) variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss).

Authors:  F E Dwulet; M D Benson
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

7.  A new transthyretin variant (Ser 24) associated with familial amyloid polyneuropathy.

Authors:  T Uemichi; M A Gertz; M D Benson
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

8.  Gelsolin-related amyloidosis. Identification of the amyloid protein in Finnish hereditary amyloidosis as a fragment of variant gelsolin.

Authors:  C P Maury
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

9.  Transthyretin Leu 68 in a form of cardiac amyloidosis.

Authors:  M R Almeida; A Hesse; A Steinmetz; B Maisch; K Altland; R P Linke; M A Gawinowicz; M J Saraiva
Journal:  Basic Res Cardiol       Date:  1991 Nov-Dec       Impact factor: 17.165

10.  A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology.

Authors:  D R Jacobson; P D Gorevic; J N Buxbaum
Journal:  Am J Hum Genet       Date:  1990-07       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.